Advice
in the absence of a submission from the holder of the marketing authorisation:
nivolumab (Opdivo®) is not recommended for use within NHSScotland.
Indication under review: Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice233KB (PDF)
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2704
- Indication:
Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 August 2024